Market Correction Wake-Up Call? 4 Dependable High-Yield Dividend Kings to the Rescue24/7 Wall Street • 03/03/25
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.Investors Business Daily • 03/03/25
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin DrugZacks Investment Research • 03/03/25
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of ObesityAccesswire • 03/03/25
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell ArteritisPRNewsWire • 02/28/25
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare GiantSeeking Alpha • 02/19/25
My Dividend Stock Portfolio: New January Dividend Record - 100 Holdings With 14 BuysSeeking Alpha • 02/19/25
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General HospitalBusiness Wire • 02/19/25
Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics TrainingPRNewsWire • 02/12/25